News | January 04, 2026
Elanco scores USDA nod for new canine allergy drug Befrena
Elanco expects Befrena to launch in the US in the first half of 2026
Elanco expects Befrena to launch in the US in the first half of 2026
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
His professional background also includes key experience at Matrix Labs and Sun Pharma
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
The accelerated review covers WCK 5222 for multiple critical infections
Applications include detailed scientific rationale and supporting clinical evidence
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Subscribe To Our Newsletter & Stay Updated
